ストックスクリーナーアプリを入手
10.08
5.88%
-0.63
アフターアワーズ：
10.27
0.19
+1.88%
Urogen Pharma Ltd (URGN) 最新ニュース
UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance
UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Plots Expansion, Brings In A New Asset - News & Insights
Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR
UroGen acquires oncolytic virus, expands cancer treatment options By Investing.com - Investing.com Nigeria
UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio -February 20, 2025 at 10:58 am EST - Marketscreener.com
UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio - Marketscreener.com
UroGen acquires oncolytic virus, expands cancer treatment options - Investing.com
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy - StockTitan
Where are the Opportunities in (URGN) - Stock Traders Daily
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World
UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
UroGen Announces Results from Subgroup Analyses of the Pivotal E - WICZ
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025 - StockTitan
D. Boral Capital Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital - MarketBeat
UroGen Pharma Ltd. Announces Results from A Long-Term Follow-Up Study with JELMYTO for Primary Treatment of Low-Grade, Upper Tract Urothelial Cancer in Adult Patients - Marketscreener.com
JELMYTO shows long-term effectiveness in cancer study By Investing.com - Investing.com Canada
JELMYTO shows long-term effectiveness in cancer study - Investing.com India
Data From A Long-Term Follow-Up Study To The Olympus Trial Published In The Journal Of Urology - Marketscreener.com
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations - StockTitan
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet - Simply Wall St
Urogen Pharma's general counsel sells $82,202 in shares - MSN
(URGN) Trading Advice - Stock Traders Daily
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells 7,379 Shares of Stock - MarketBeat
SG Americas Securities LLC Has $216,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares - MarketBeat
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells $82,202.06 in Stock - Armenian Reporter
UroGen Pharma's chief medical officer sells shares worth $50,698 - MSN
UroGen Pharma's chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Canada
UroGen Pharma’s chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Nigeria
Urogen Pharma's general counsel sells $82,202 in shares By Investing.com - Investing.com South Africa
URGN (UroGen Pharma) Revenue per Share : $2.39 (TTM As of Sep. 2024) - GuruFocus.com
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
URGN (UroGen Pharma) EPS without NRI : $-2.60 (TTM As of Sep. 2024) - GuruFocus.com
UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian
JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
JPMorgan Chase & Co. Grows Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts - MarketBeat
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
JELMYTO shows promise in long-term cancer treatment study By Investing.com - Investing.com Australia
JELMYTO shows promise in long-term cancer treatment study - Investing.com
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Bladder Cancer Clinical and Non-Clinical Studies, Key - openPR
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):